Non-interventional, post-authorization safety study (PASS) of patients treated with commercially available liso-cel (lisocabtagene maraleucel) for large B-cell lymphomas (JCAR017-BCM-005) First published 20/03/2023 Last updated 02/07/2024 EU PAS number:EUPAS103855 Study Ongoing